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Programmed cell elimination is an important pathological
mediator of disease. Multiple pathways to programmed cell
death have been delineated, including apoptosis, autophagy
and programmed necrosis. Cross-talk between the signaling
pathways mediating each process has made it difficult to
define specific mechanisms of in vivo programmed cell
death. For this reason, many “apoptotic” diseases may involve
other death signaling pathways. Recent advances in genetic
complementation using mouse knockout models are helping
to dissect apoptotic and necrotic cell death in different
pathological states. The current state of research in this area
is reviewed, focusing upon new findings describing the
role of programmed necrosis induced by the mitochondrial
permeability transition in mouse models of heart failure and
diabetes.

Introduction
Like people, cells are born, they live for a time and (with a few
notable exceptions) they die. Indeed, cell death is an essential
part of tissue renewal. The linkage between cell death and birth
is bi-directional. An unexpected loss of cells accelerates growth
of similar cells in a healing process that is essential for functional
homeostasis, whereas the need to replace senescent cells with
new cells requires programmed elimination of older, damaged or
less functional tissue. An appreciation of these two pathophysiological contexts led to the classical paradigm of cell death being
either mandated or elective. Mandated cell death (often referred
to as “necrosis”) is typically the consequence of trauma or tissue
damage, and has therefore been anthropomorphically labeled cell
murder; like murder, mandated cell death is not tidy. The cellular
response to lethal injury involves cell swelling, loss of membrane
integrity and release of chemical mediators that can cause collateral damage. From the victim’s (cell/tissue/organ) perspective,
this form of cell death is random and therefore unplanned. For
the organism there is a crime scene to clean and cellular corpses to
remove. Critical functions normally performed by the murdered
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cells are interrupted by their absence, and can be further disrupted by first responders (i.e., inflammation).
By contrast, the conventional view is that elective cell death
is much cleaner for all concerned. This is certainly the case for
apoptotic cell death, as originally conceived by Vogt in the 19th
century and more strictly defined by Kerr, Wyllie and Curie in
1972.1 The best anthropomorphism for apoptosis is probably
“assisted cell suicide” as there is extensive molecular and cellular
infrastructure that supports this form of elective cell termination.
Apoptotic cell death is the deliberate result of processes initiated
in response to developmental cues or external factors that are,
themselves, non-lethal. In either case, the cell decides to remove
itself, packs up its constituent proteins, organelles and DNA for
easy removal and essentially “turns off and fades away”. As a
consequence of this planning and effort, the untoward collateral
effects associated with mandated cell death are largely avoided.
Elective cell death is essential for normal tissue development
and homeostasis, and is therefore tightly regulated. Apoptotic
cell death is an evolutionarily conserved process resulting from
cascade activation of caspase cysteine proteases downstream of
cytokine death receptors (the extrinsic apoptosis pathway) or
transcriptionally and post-translationally regulated mitochondrial-localized Bcl2 family members (the intrinsic apoptosis
pathway; reviewed in ref. 2). Dysregulation of programmed cell
death perturbs normal tissue homeostasis and is implicated in
cancer (too little apoptosis), Alzheimer disease (inappropriate
apoptosis) and other chronic degenerative conditions.3-5
In recent years, this comfortable and straightforward paradigm of mandated versus elective cell death has been complicated
by the recognition of multiple apoptotic and non-apoptotic pathways for programmed cell elimination. In particular, it is clear
that cell death also occurs via a phenomenon of “programmed
necrosis”, which is elective like apoptosis, but untidy like necrosis.
To extend the previous anthropmorphisms, programmed necrosis is neither cell murder, nor assisted cell suicide, but is more like
the cell figuratively throwing itself in front of an oncoming bus.
The result is elective cell elimination in a manner that is functionally disruptive and activates inflammatory mechanisms. The
molecular and biochemical pathways that regulate, initiate and
mediate programmed cell necrosis are only now being defined,
and it likely to be mediated by multiple non-apoptotic mechanisms leading to abrupt metabolic shut-down. It is ironic that
John Foxton Ross Kerr, the father of modern apoptosis, originally
used the term “programmed cell necrosis” to describe his concept
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of natural cell death. The various terms currently being used to
describe non-apoptotic elective cell death (programmed necrosis,
regulated necrosis, necroptosis) continue to be confusing as none
are mechanistically based.6,7
Apoptosis and programmed necrosis are mediated by distinct
signaling pathways, but the two processes can be difficult to differentiate in vivo. There is no specific histochemical marker for
programmed necrosis. Dystrophic calcification and complement
activation have been used to identify necrotic tissue, but these
markers do not differentiate between standard and programmed
tissue necrosis. On the other hand, conventional markers for
apoptosis (cytochrome c release, activate caspases and TUNEL
labeling) do not exclude programmed necrosis because mitochondrial swelling and outer membrane rupture that are the primary
cause of programmed necrosis secondarily release cytochrome
c into the cytosol. Although this activates apoptosis signaling,
reversal of ATP production in cells undergoing necrosis prevents
the orderly (and energy-requiring) dismantling of the cellular
machinery, and so they don’t die of apoptosis. Concomitant
activation of apoptotic markers in cells undergoing programmed
necrosis seems likely to have implicated apoptosis in diseases
where programmed necrosis is a primary mechanism of elective
cell elimination.
Here, new findings linking programmed necrosis mediated
via the mitochondrial permeability transition with diabetes and
heart failure are explored. The striking benefits that accrued from
genetic interruption of programmed necrosis in mouse models of
these two human conditions should prompt a re-evaluation of
widely held notions that apoptotic cell death is the major effector
of pathological cell loss.
Pancreatic β-cell Deficiency in Diabetes;
Apoptosis or Programmed Necrosis?
A simple operational definition of diabetes is: any condition in
which endogenous insulin production and secretion are insufficient to meet metabolic demands. Mechanistically, this includes
conditions where there is an absolute paucity of insulin in individuals of normal body mass (type 1 diabetes),8 or where there is
an abundance of insulin in individuals whose need is still greater,
due to increased body mass and/or insulin resistance (type 2 diabetes).9,10 Insulin is produced exclusively by β-cells located within
the pancreatic Islets of Langerhans, and these cells have the ability to undergo hyperplasia in response to metabolic stress.11 Both
forms of diabetes are causally linked to (absolute or relative)
β-cell deficiency,12 and in many instances attributed to increased
β-cell apoptosis.13-15 However, targeting β-cell apoptosis has
either been incompletely successful in preventing diabetes,16 or
has unmasked latent oncogenic potential.17 These results point
to a parallel programmed death pathway in pancreatic β-cells.18
We recently used genetic complementation in a mouse diabetes model to interrogate the role of programmed β-cell necrosis
caused by opening of the mitochondrial permeability transition
pore (MPTP). The MPTP is a non-selective pore in the mitochondrial inner membrane that opens in response to increased
local calcium concentration.19 Proton diffusion through the

www.landesbioscience.com

MPTP dissipates the normal mitochondrial pH gradient and
inner membrane electrochemical potential (Δψm) that are
required for ATP production through oxidative phosphorylation.20 MPTP opening therefore reverses ATP synthesis, and the
mitochondrion becomes a net ATP consumer. The loss of cellular
ATP subsequent to MPTP opening ignites a cascade of metabolic
dysfunction that can ultimately lead to cell necrosis.
Another consequence of MPTP opening is osmotic mitochondrial swelling that disrupts outer mitochondrial membranes,
permitting cytochrome c to be released into the cytosol from
the mitochondrial inter-membranous space. Although MPTPdependent cytochrome c release can activate the apoptotic
caspase cascade, cell death by apoptosis requires ATP that is critically deficient after the mitochondrial permeability transition.
Thus, cell death subsequent to the mitochondrial permeability
transition proceeds via metabolic shutdown and programmed
necrosis, rather than apoptosis. Because cytochrome c release and
its sequelae occur in both apoptosis and MPTP-dependent programmed cell necrosis, they do not reliably indicate one or the
other cell death pathway.
The structural components of the MPTP are not completely
clear.21,22 Core MPTP elements consist of the voltage-dependent anion channel (VDAC), the adenine nucleotide translocator (ANT) and cyclophilin D (CyP-D). The VDAC was long
considered to be an essential component of the MPTP,23-25 but
genetic models have convincingly refuted this notion; the VDAC
is dispensable for both Bcl2 family member-mediated apoptosis
and MPTP-dependent necrosis.26 Likewise, gene ablation studies
in mice showed that mitochondria lacking ANT can undergo
permeability transition.27 ANTs may function as phosphate- and
calcium-sensitive MPTP regulators. In contrast, three independent groups have reported that genetic ablation of CyP-D is sufficient to eliminate the mitochondrial permeability transition
without affecting conventional mitochondrial-mediated apoptosis.6,28,29 For this reason, genetic Ppif ablation has been used to
demonstrate the role of MPTP opening and programmed cell
necrosis in mouse models of Alzheimer’s disease, muscular dystrophy, diabetes mellitus and heart failure.30-33
Our studies of MPTP-mediated programmed β-cell death
in diabetes used a genetic mouse model, the Pdx1 hemizygous
mouse.32 PDX1 (pancreatic and duodenal homeobox factor 1;
also called insulin promoter factor 1, IPF1) is a necessary transcription factor for pancreas development. Loss of function
human Pdx1 mutations are linked with pancreatic agenesis,
heritable maturity onset diabetes of the young and type 2 diabetes.34-36 Likewise, germ-line homozygous Pdx1 gene ablation in
mice produces lethal pancreatic agenesis,37 whereas heterozygous
germ-line or β-cell specific Pdx1 null mutations result in a diabetes phenotype.38,39 Several cellular mechanisms have been proposed for loss of insulin-producing pancreatic β-cells in the Pdx1
deficient model of diabetes, including decreased proliferation,40
and increased programmed cell death through apoptosis and
autophagy.13,41,42 The prevailing opinion has been that increased
β-cell death, and not decreased proliferation, is the more important mechanism, with apoptosis most often implicated.14 As
indicated above however, the standard markers of apoptosis do
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not discriminate between apoptosis
and programmed necrosis. Therefore,
it was possible that programmed β-cell
necrosis in Pdx1 insufficiency had been
mis-identified as apoptosis based on
findings of cytochrome c release and
β-cell TUNEL positivity. We examined
this possibility in cultured mouse insulinoma-derived β-cells (MIN6 cells),
using shRNA to suppress Pdx1 expression, TUNEL as a measure of apoptosis
signaling, rhodamine 123 to measure
integrity of the MPTP and propidium
iodide to assess cell death in a pathwayindependent manner.32 As expected,
Pdx1 suppression increased TUNEL
positivity and β-cell death. Importantly,
it also opened β-cell MPTPs, which is
not a direct effect of apoptosis. To determine if MPTP opening was a primary
or secondary effect of Pdx1 suppression,
we treated the cells with cyclosporin A,
a pharmacological inhibitor of CyP-D
(the essential protein for MPTP opening). Cyclosporin A prevented MPTP
opening and significantly reduced
Pdx1-deficient β-cell TUNEL positivity and death. This result suggested that
MPTP opening could be responsible for
as much as half of cultured β-cell death
induced by Pdx1 deficiency.
Figure 1. Schematic depiction of programmed β-cell death pathways implicated in diabetes caused
We used genetic complementaby Pdx1 haplo-insufficiency. Deficiency of transcription factor Pdx1 likely alters gene expression, action with ppif null mice (the ppif gene
tivating pathways that induce apoptosis via mitochondrial outer membrane permeabilization (left)
encodes CyP-D) to assess the role of
and programmed necrosis via the mitochondrial permeability transition (right). Pancreatic β-cell
MPTP-induced β-cell necrosis in
autophagy is also induced by Pdx1 insufficiency, but its role in programmed cell death is currently
murine diabetes caused by Pdx1 haplounclear.
insufficiency. Pancreatic islets of Pdx1
haplo-insufficient mice are characteristically small, with strikingly reduced numbers of insulin-con- Together, these studies implicate MPTP-mediated β-cell necrosis
taining β-cells. Eliminating functional MPTPs through ppif as an important component of pathological programmed β-cell
ablation increased islet size and decreased TUNEL labeling. death caused by Pdx1 deficiency, and support a co-equal role
We also stained the pancreata for complement 9, a component for conventional apoptosis through the mitochondrial pathway
of the complement membrane attack complex that is part of the (Fig. 1). Prevention of diabetes with only partial normalization
inflammatory response to cell necrosis. Complement 9 staining of β-cell mass in Pdx1-deficient mice lacking functional MPTP
was increased in Pdx1 haplo-insufficient islets, but was normal- likely reflects physiological pancreatic insulin reserve.
ized by concomitant ppif ablation. This histological “rescue” was
observed in both adult and neonatal pancreata, revealing a role for Programmed Cardiac Myocyte Death in Heart Failure
MPTP-mediated programmed β-cell necrosis during embryonic
Because adult cardiac myocytes are terminally differentiated and
development and for β-cell homeostasis in the adult pancreas.
Finally, we determined the consequences of preventing MPTP- replication-deficient, normal tissue homeostatic mechanisms do
mediated programmed β-cell necrosis on the diabetic phenotype not apply. Although these cells proliferate during cardiac develof adult Pdx1 deficient mice. Diabetes in this model is mani- opment, shortly after birth the rate of cell division drops to levfested by decreased circulating insulin and increased blood glu- els that are difficult to quantify, but are certainly inadequate for
cose levels measured either at baseline or in response to an acute meaningful tissue regeneration. Because there is no cardiac myoglucose challenge. Ablation of ppif in Pdx1 haplo-insufficient cyte replacement, there is no normal level of programmed cardiac
mice almost completely normalized both of these parameters. myocyte death. Even after tissue injury or under conditions of
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non-lethal stress, programmed cardiac myocyte elimination is
pathological. Nevertheless, apoptosis is observed in cardiac myocytes of failing, ischemic and pressure overloaded hearts, and is
implicated in progression to cardiomyopathy.43 Indeed, a genetic
program for programmed cell death is one of the hallmarks of the
“compensatory” hypertrophic reaction to cardiac overload.44,45
Using microarray-based RNA profiling of Gq transgenic
mice, our laboratory first described a genetic program for cardiac myocyte death in hypertrophied hearts. Gαq (the alpha
sub-unit of the heterotrimeric Gq signaling protein) transduces
signaling through cardiac myocyte hypertrophy pathways stimulated by angiotensin II, α1-adrenergic and endothelin receptors. The Gq mouse expresses four to five times the normal
amount of myocardial Gαq, resulting in ligand-independent
Gq signaling and autonomous cardiac hypertrophy with many
of the pathological characteristics of pressure overload hypertrophy (but without pressure overload).46 Shortly thereafter we
further described progression to dilated cardiomyopathy mediated by Gαq-stimulated cardiomyocyte apoptosis,47,48 suggesting a link between cardiomyocyte hypertrophic growth and
programmed death. Specifics of this linkage were established
by transcriptional profiling, which identified increased levels of
several death pathway genes in Gq hearts.49,50 One of these death
genes encoded Nix (also called BNip3L), a member of the small
BH3-like only subclass of mitochondrial-targeted Bcl2 apoptosis regulating proteins.
Because they are the sites of action for Nix and other Bcl2
family proteins, mitochondria have been called the “gatekeepers” of programmed cell death.51 Bax and Bak are the essential
pore-forming proteins that permeabilize mitochondrial outer
membranes, leading to cytochrome c release and intrinsic apoptosis signaling. Pore-formation by Bax and Bak is facilitated by
pro-apoptotic BH3 domain-only factors, including Nix/BNip3L
that we identified in the heart. Nix and other BH3-only factors
hetero-dimerize with anti-apoptotic Bcl2 and Bclx l, which prevents mitochondrial pore formation by Bax and Bak.2 Dynamic
regulation of Nix, Bax, Bak and other pro- or anti-apoptotic Bcl2
family proteins is characteristic of heart failure (reviewed in ref.
52). A protein kinase C/SP1-dependent mechanism for transcriptional upregulation appears to be responsible for increased
Nix gene expression in cardiac hypertrophy.53
We used cardiac transgenesis to determine the in vivo consequences of Nix upregulation in hearts, independent of Gq,
cardiac hypertrophy or any hemodynamic stress or cardiac
injury. Nix expression was directed specifically to cardiac myocytes using the MYH6 promoter, which is transcriptionally
activated only after birth. The result of post-natal cardiac-specific Nix expression was mice that were born normal, but succumbed to progressive dilated cardiomyopathy on the seventh
to tenth day of life. TUNEL staining was positive in 15–20%
of cardiac myocytes, implicating massive programmed cardiac myocyte death in this form of fulminant heart failure.50 A
subsequent study in which Nix was conditionally expressed in
the heart revealed synergism between Nix and pressure overload stress for inducing apoptotic heart failure in adult hearts,54
uncovering functional coordination by Nix of transcriptional
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and physiological stimuli for programmed cardiomyocyte
elimination.
Based on the above results, we hypothesized that Nix (and the
programmed cardiac myocyte death it produces) mediates progression to heart failure in pressure overload cardiac hypertrophy.
To test this idea, we created cardiac-specific Nix gene knockout
mice, subjected them to surgical pressure overload and compared
cardiomyocyte TUNEL labeling, ventricular remodeling and
cardiac function to identically pressure overloaded hearts of mice
with intact Nix genes. Cardiac Nix knockout mice exhibited
only half the typical rate of cardiomyocyte TUNEL positivity
and myocardial fibrosis after pressure overloading and exhibited
almost no ventricular dilation, wall thinning or decrease in contractile systolic function.55 These data identified Nix as a critical
inducible factor mediating programmed cardiac myocyte death
in pressure overload hypertrophy and established a causal role for
Nix in adverse ventricular remodeling and development of heart
failure.
Delineation of Multiple Nix-Stimulated
Cell Death Pathways
Like all pro-apoptotic Bcl2 family members, Nix stimulates
caspase-dependent apoptosis resulting from mitochondrial outer
membrane permeabilization. In cardiac myocytes and other cell
types, Nix localizes to mitochondria and induces cytochrome c
release that is followed by caspase activation and oligonucleosomal DNA degradation.50 However, we recently observed that only
~80% of transfected Nix localizes to mitochondria; the remainder is localized to endoplasmic reticulum (ER) or the analogous
structure in cardiac myocytes, sarcoplasmic reticulum (SR).56 We
further observed a direct relationship between cardiac myocyte
Nix levels and cardiomyocyte SR calcium stores: Nix overexpression increased SR calcium content by ~20%, whereas Nix gene
ablation decreased SR calcium content by ~20%. Although SR
calcium release is a critical regulator of myocyte contraction, we
postulated that SR-localized Nix did not meaningfully regulate
cardiac contractility. Rather, we felt that SR calcium might play a
role in Nix-mediated cell death. Indeed, restoration of normal SR
calcium levels in Nix knockout mice by genetic complementation
with the phospholamban null mouse reversed the cardio-protective effects observed with Nix ablation, increasing programmed
cardiomyocyte death, exaggerating the cardiomyopathy and
increasing mortality. These results linked SR calcium to programmed cardiac myocyte death and heart failure produced by
Nix.
We considered that reticular-mitochondrial calcium crosstalk57 stimulated by SR-localized Nix could induce the “necrotic”
pathway to programmed cardiomyocyte death. If this were the
case, cardiomyocyte “apoptosis” we and others have reported
based on TUNEL staining might instead be a secondary effect of
mitochondrial rupture after MPTP opening, as we had observed
in pancreatic β-cells (see above). However, little was known about
the role of calcium and MPTP opening in programmed cardiac
myocyte death. While calcium is used to stimulate MPTP opening in laboratory studies using isolated mitochondria, it has been
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suggested that the MPTP is relatively calcium insensitive in vivo
due to stabilization by cytosolic factors.58 Because dual Nix localization to mitochondria and reticulum confounds experimentation designed to identify calcium-stimulated non-apoptotic
death pathways induced by reticular Nix, we created mitochondria-directed and ER/SR-directed Nix mutants and analyzed
their effects after recombinant expression in Nix null embryonic
fibroblasts.33 Mitochondrial-directed Nix stimulated cell death
marked by caspase activation, but normal Δψm, i.e., apoptosis. In
contrast, reticular-directed Nix stimulated cell death preceded by
MPTP opening and dissipation of Δψm, i.e., necrosis, but in which
caspase activation attributed to cytochrome c release after MPTP
opening and outer mitochondrial membrane rupture was also
observed. Using the same experimental design as in our diabetes
studies, we found that pharmacological (cyclosporin A) or genetic
(CyP-D, Ppif ablation) inhibition of the MPTP prevented cell
death induced by reticular Nix, but not by mitochondrial Nix.33
Importantly, apoptosis induced by mitochondrial-directed Nix
required Bax or Bak, whereas programmed cell necrosis induced
by reticular-directed Nix showed no requirement for Bax and
Bak. These results demonstrated that mitochondrial-directed
Nix specifically activates conventional Bax/Bak-dependent mitochondrial pathway apoptosis, whereas reticular-directed Nix specifically induces MPTP-dependent programmed cell necrosis by
increasing reticular calcium concentration and calcium delivery
to mitochondria (Fig. 2).
To determine the relative contribution of Nix-mediated
apoptosis versus programmed necrosis to in vivo heart failure we
translated the above experimental design to the in vivo murine
system and created cardiac-specific conditional transgenic mice
expressing mitochondrial-directed or reticular-directed Nix
mutants.33 The in vivo dilated cardiomyopathy phenotypes
and extent of cardiac myocyte TUNEL labeling (which does
not differentiate between apoptosis and programmed necrosis)
were similar in mitochondrial-directed and reticular-directed
Nix mutant mice. However, cardiac myocyte necrosis visualized
by anti-complement 9 staining was observed only in reticulardirected mutant Nix mice. Transmission electron microscopy
likewise revealed mitochondrial swelling, matrix degeneration
and outer membrane disruption only in cardiomyocytes from
reticular-directed Nix mice. A causal link between MPTP
opening in reticular-directed Nix-induced cardiac myocyte
death was established by concomitant ablation of ppif (encoding CyP-D) in the Nix mutant cardiomyopathy models. ppif
ablation prevented cardiomyocyte death (TUNEL labeling)
and complement 9 staining in reticular-directed Nix expressing
mice, normalizing mitochondrial ultrastructure and preventing
the dilated cardiomyopathy. In contrast, ppif ablation did little
to improve the apoptotic cardiomyopathy produced by mitochondrial-directed Nix. These findings show that an important aspect of Nix-mediated cell death is programmed necrosis
mediated by SR-mitochondrial crosstalk. As other reports have
implicated cardiac myocyte or sarcoplasmic reticular calcium levels in cardiac injury and heart failure progression,59-61
MTPT opening stimulated by reticular-mitochondrial calcium
cross-talk may play a greater role than previously suspected in
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Figure 2. Schematic depiction of multiple Nix-induced pathways for
cell death in heart failure. Transcriptionally upregulated Nix localizes
either to mitochondria, where it interacts with Bax and Bak to induce
apoptosis via outer membrane permeabilization, or to calcium-containing sarcoplasmic reticulum (SR), where it increases calcium stores and
activates the mitochondrial permeability transition pore (MPTP) independent of Bax and Bak. Mitochondrial disruption subsequent to MPTP
opening leads to metabolic shutdown and death via programmed
necrosis.

hypertrophy decompensation and the progression to overt heart
failure.
Conclusions
It may be time to revise our perceptions of the role for apoptosis
in chronic disease. In general, apoptosis seems to be a good thing.
It is an essential feature of normal embryonic tissue development
and adult tissue homeostasis. When normal apoptotic mechanisms are interrupted by natural or experimental mutation, the
consequences of unopposed cell growth can be tumor or malignancy. Because the assays used to define apoptosis are not specific
for that mechanism, “apoptosis” has been implicated and vilified in variety of chronic diseases associated with abnormal cell
death. An increased appreciation that all programmed cell death
is not apoptotic, and especially for the role of the mitochondrial
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permeability transition and programmed necrosis, may reveal
that non-apoptotic programmed cell death plays a major role in
pathological programmed cell elimination. Chronic diseases in
which MPTP-dependent programmed cell death has been implicated include Alzheimer’s disease,30 muscular dystrophy,31 amyotrophic lateral sclerosis,62 heart failure,33 and diabetes.32 It is likely
that this list will expand further.
The dichotomy between apoptotic and programmed necrotic
cell death is mechanistically useful, but is almost certainly blurred
in the in vivo context. As noted previously, a cell may initiate the
process for apoptosis via permeabilization of mitochondrial outer
membranes by Bax and Bak, but if there is insufficient ATP to
complete the process, the ultimate consequence may be necrotic
death from metabolic shutdown, or even a state of severe, but
non-lethal dysfunction that some have describes as a “zombie”
cell. It is also likely that some mitochondria within a single cell
will undergo outer membrane permeabilization (apoptosis), others will undergo the permeability transition (necrosis), and some
fraction will continue to function normally for at least a while.
Under these circumstances, the determination of whether the cell
will die, and the mechanism for programmed cell elimination,
would be the aggregate of all relevant external factors and intracellular conditions.
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